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The current interest in recombinant factor VIII (rFVIII) products stems from the fact that
they offer a technological solution to prolonging the half-life of and reducing the risk of
formation of alloantibodies (inhibitors) against FVIII in treated patients with hemophilia
A (HA). The Italian health care system has authorized the use of a wide range of rFVIII
concentrates of the first, second, and third generation, as well as new innovative rFVIII
preparates with an extended half-life (EHL) (Kogenate FS®-Bayer, belonging to the
second generation and replaced since 2017 by a product consisting of the samemodified
molecule; because it is only available until the end of the current year, it will not be
considered in this review). Some of these products have unique pharmacodynamic and
pharmacokinetic (PK) profiles, including an EHL. The first-generation full-length rFVIII (FL-
rFVIII), octocog alfa (Recombinate® Baxter/BIOVIIIx), although the oldest rFVIII product,
has several desirable features. Third-generation products include two modified octocog
alfa molecules (Advate®, Shire; Kovaltry®, Bayer) as well as the B domain-deleted
rFVIII (BDD-rFVIII) moroctocog alfa (ReFacto®-Pfizer). The B domain-truncated (BDT-
rFVIII) turoctocog alfa (NovoEight®, Novo Nordisk), the BDD-rFVIII simoctocog alfa
(Nuwiq®, Kedrion), the single-chain BDT-rVIII lonoctocog alfa (Afstyla®, CSL Behring),
and the BDD-rFVIIIFc efmoroctocog alfa (Elocta®, Sobi-Biogen) are new, innovative
products. Simoctocog alfa, because its peculiarities, is considered a fourth-generation
rFVIII concentrate. Turoctocog alfa, simoctocog alfa, and lonoctocog alfa have a high
affinity for von Willebrand factor (vWF) that reduces renal clearance and prolongs the
half-life of rFVIII. Efmoroctocog alfa, a first-in-class rFVIII-Fc fusion protein (rFVIIIFc), has
a half-life 1.5–1.8 times longer than that of conventional plasma-derived FVIII (pd-rFVIII)
and other rFVIII products. Clinical studies have evaluated the efficacy, safety, and inhibitor
development of all these innovative concentrates in both previously treated (PTPs) and
untreated patients (PUPs). This review considers the rFVIII products that are indicated
for the treatment of patients with severe HA, focusing on those that are commercially
available in Italy. Their PK characteristics, immunogenicity, and clinical benefits are
discussed and compared.
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INTRODUCTION
The treatment of HA has dramatically improved since
the 1990s, when the outbreak of blood-borne infections,
mainly due to the human immunodeficiency and hepatitis
viruses, caused high rates of death and co-morbidities
in many patients (1). This worldwide situation led
to the implementation of virus inactivation in the
manufacture of pd-FVIII and rFVIII products, improving
replacement therapy.
In addition, many HA patients develop inhibitors
in response to FVIII injections. Thus, since 2008,
the European Haemophilia Safety Surveillance System
(EUHASS; www.EUHASS.org) has carried out safety
monitoring of substitution therapies for patients with
hemophilia (2).
All rFVIII products have an improved safety profile, as
their production includes virus inactivation procedures similar
to those used in pd-FVIII concentrates (in first-generation
products, human albumin underwent pasteurization at 60◦C
for 10 h; a solvent/detergent (S/D) step and nanofiltration
were employed in the second and third generations, and
chromatographic purification techniques were also performed)
and furthermore the progressive removal of human and animal
proteins from the final formulation. The different generations
of rFVIII products reflect the evolution of the methods used in
their manufacture. First-generation rFVIII production methods
include the use of animal proteins in the cell culture medium
and the addition of human serum albumin to stabilize the
recombinant product; the culture medium of second-generation
rFVIII contains human- or animal-derived proteins but not
human albumin; finally, the most recent, third-generation rFVIII
products have no added human- or animal-derived proteins
at all.
For patients with severe HA, prophylaxis with FVIII
concentrates is the main treatment regimen to reduce joint
bleeding and other types of hemorrhage, thereby improving
the health-related quality of life (HRQoL) of both patients and
their caregivers (3, 4). Moreover, prophylaxis reduces inhibitor
formation, which is the major adverse event of hemophilia
treatment (5).
HA prophylaxis usually consists of intravenous FVIII
injections every other day or three times per week due
to the short half-life of FVIII of approximately 12 h (6).
However, the need for frequent injections is a considerable
burden for patients and their caregivers, particularly in
children and in those patients with poor venous access. The
development of EHL rFVIII products has slightly improved
the management of these patients by allowing a reduction in
the dose frequency, which in turn has increased adherence to
treatment (7).
This review summarizes the characteristics of the rFVIII
products currently available in Italy for the treatment of
severe HA (Table 1). The potential clinical benefits of these
concentrates, as well as safety concerns including high titer
inhibitor formation, are discussed.
First-Generation Product
Recombinate®
Recombinate R© (octocog alfa, Baxter Biotech; distributed in Italy
by BIOVIIIx) is the only one of two first-generation rFVIII
concentrates that is still commercially available in Italy. It is
derived from a conditioned medium of chinese hamster ovary
(CHO) cell cultures transfected with cDNAs for FVIII (8–10).
Human albumin, polyethylene glycol (PEG) 3350 (3 mg/ml),
sodium chloride, calcium chloride, and histidine are added as
stabilizers. The product currently used in Italy is manufactured in
Belgium and does not contain polysorbate 80. The co-expression
of recombinant vWF with rFVIII contributes to the stabilization
of the product.
Beginning in 1990, a multicenter, multinational, prospective
clinical trial of Recombinate R© was conducted on PUPs with
severe/moderate HA (baseline FVIII ≤2%) in order to evaluate
the safety and efficacy of the product, including the development
of inhibitors (11). Of the 79 PUPs enrolled, 76 received at least
one infusion of the concentrate, and the 72 patients (91%) who
continued in the study were tested for rFVIII inhibitors. Adverse
events were reported after nine of the 12,156 rFVIII infusions
administered to the cohort (0.074%), but none were defined
as serious.
Of the 72 patients, 22 (30.5%) developed rFVIII inhibitors:
a low titer (≤5 BU) was measured in 13 (59%) patients and
a high titer (>5 BU) in 9 (40.9%) patients. In 12 of the 22
patients (54.5%), the inhibitors became undetectable, including
in 11 patients in the low-titer group. At the end of the study, nine
of the 72 patients (12.5%) still had a high titer of inhibitors.
Ewenstein et al., in a prospective pharmacovigilance study that
considered the incidence of inhibitor development worldwide
in patients treated with Recombinate R©, demonstrated that the
overall percentage was 11.9% (95% confidence interval [CI 5.05–
28.0%]) for PUPs and 0.123% (CI: 0.030–0.512%) for PTPs. The
incidence of high-titer inhibitors (>5 BU) was 5.96% (CI: 3.00–
11.8%) for PUPs and 0.0554% (CI: 0.0113–0.271%) for PTPs (12).
A trial comparing the PK of Recombinate R© with that of
pd-FVIII enrolled 69 PTPs with HA (67 with severe and two
with moderate disease), who participated for a median of 3.7
(1.0–5.7) years with the aim of comparing the PK of rFVIII
with that of pd-FVIII. The safety and long-term home-treatment
efficacy of rFVIII was also assessed (13). At study entry, 44
patients were HIV seropositive and 25 were seronegative. Three
patients had a history of inhibitors, but not at study entry. The
results showed that the mean incremental recovery for rFVIII at
baseline was 2.4%/IU/kg, essentially the same as that of pd-FVIII
(2.5%/IU/kg). Furthermore, there was no significant change in
recovery over a 30-month period. The mean in vivo half-life of
rFVIII and pd-FVIII at baseline was the same: 14.7 h. However,
over time, rFVIII demonstrated a statistically significant trend (p
= 0.015) of a longer mean half-life, as determined at months 18
and 24 (Table 2).
The Evaluation Study on Prophylaxis: a Randomized
Italian Trial (ESPRIT) compared prophylaxis with on-demand
treatment with the aim of preventing joint bleeding and joint
damage in children with severe HA (14). Forty of seventy-two
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TABLE 1 | Panel of recombinant factor VIII (rFVIII) products currently available in Italy.
Molecule Brand Protein structure Manufacturer/distributor Cell line
First-generation rFVIII
Octocog Alfa Recombinate® Full-length rFVIII +
albumin+pegylation
Baxter/Bioviiix Chinese hamster
ovary (CHO)
Third-generation rFVIII
Octocog alfa Advate® Full-length rFVIII; albumin-free Shire CHO
Moroctocog Alfa ReFacto AF® BDD rFVIII; albumin-free Pfizer CHO
Innovative third-generation rFVIII
Octocog alfa Kovaltry® Full-length rFVIII (glycosylation sites,
sulfation of tyrosine sites)
Bayer Baby hamster kidney
Turoctocog alfa NovoEight® BTD rFVIII
(glycosylation sites, sulfation of
tyrosine sites)
Novo Nordisk CHO
Simoctocog Alfa Nuwiq® BDD rFVIII Octapharma/Kedrion Human embryonic
kidney (HEK)
Lonoctocog alfa Afstyla® Single-chain rFVIII
BDT-rFVIII
CSL-Bhering CHO
Extended half-life rFVIII
Efmoroctocog alfa Elocta® BDD rFVIII-Fc fusion Biogen Inc./Sobi HEK
TABLE 2 | Time course of the half-life of rFVIII (Recombinate® ) and a comparison
with plasma-derived FVIII III (pdFVIII) [from (13)].
Months n Half-life (h)
(mean ± SD)
Range P-value
(vs.
baseline)*
pd-FVIII 61 14.7 ± 5.1 5.8–40.8 1
rFVIII
(Recombinate® )
baseline
65 14.7 ± 4.9 6.8–34.7 –
3 58 15.3 ± 50 5.6–30.6 0.52
6 62 15.3 ± 5.0 6.4–27.5 0.47
9 12 16.7 ± 7.7 10.8–34.7 0.25
12 61 16.0 ± 8.7 8.1–60.2 0.32
15 11 16.9 ± 8.5 10.7–39.1 0.41
18 55 18.4 ± 7.1 9.0–41.9 0.002
21 4 14.5 ± 3.3 11.0–17.5 0.93
24 10 18.1 ± 4.2 10.9–25.8 0.04
27 3 15.7 ± 5.1 10.9–21.1 0.74
30 48 15.2 ± 4.9 7.5–28.7 0.59
*p = 0.015 (Kruskal–Wallis test).
eligible patients ranging in age from 1 to 7 years, completed
the study. Twenty were randomly assigned to be treated
prophylactically with Recombinate R© at a dose of 25/IU kg three
times a week on nonconsecutive days and nineteen on-demand
with the same product at a dose ≥25/IU kg. The results showed
that children randomized to the prophylaxis regimen had
significantly fewer of all hemorrhagic events and joint bleeding
episodes than patients in the on-demand group (P < 0.05). Of
the five patients who developed inhibitors (12.5%), three were
in the prophylaxis group and developed inhibitors after 24–48
exposure days (EDs). The remaining two patients, who were in
the on-demand group, developed inhibitors at 20 and 2 EDs. No
patient suffered from life- or limb-threatening bleeding or from
hemorrhage that required hospitalization.
Third-Generation Products
Advate®
In 2003, a plasma/albumin-free formulation of octocog alfa
containing sucrose was introduced as the first third-generation
rFVIII originating from its precursor Recombinate R©. The
adapted recombinant system used in the production of the rFVIII
molecule includes culture medium free of human- or animal-
derived additives. The CHO cell line co-expressing FL-FVIII
and vWF has not undergone any further genetic manipulations,
and the cDNA sequences encoding the recombinant proteins
are identical to those used to obtain Recombinate R©. Processing
includes an S/D step, a viral inactivation that preserves the
structural and functional integrity of the rFVIII molecule but
inactivates lipid-enveloped infectious agents (15). Following the
S/D step, the eluate is further purified using anion exchange
chromatography. The newly introduced rFVIII, given the name
Advate R©, contains the following stabilizers and excipients:
mannitol, trehalose, sodium chloride, histidine, Tris, calcium
chloride, polysorbate 80, and glutathione.
The PK of Advate R© has been evaluated in adults and children
based on FVIII activity measurements in blood samples obtained
up to 48 h following each infusion. The mean half-life values
in adults and children differ as a function of patient age
(Tables 3, 4).
Advate R© has been evaluated in 11 clinical trials in PTPs and
in one trial in PUPs with severe to moderate HA (FVIII ≤2% of
normal). The five completed clinical trials have demonstrated the
safety and efficacy of Advate R© in adult and pediatric PTPs, for
both prophylactic and on-demand treatment regimens and for
perioperative hemostatic coverage (Table 5) (17).
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A three-part study investigated the use of Advate R© in 10- to
65-year-old PTPs without previous or detectable inhibitors. Fifty-
six patients were randomized to Part 1 of the study, comparing
the PK of Advate R© with that of Recombinate R©. Patients with
severe or moderate HA (baseline FVIII ≤2%) received an initial
infusion (50 ± 5 IU/kg). Bioequivalence between the older and
newer products in terms of PK was demonstrated. Part 2 of
the study evaluated the efficacy, safety, and immunogenicity of
Advate R© in 108 patients (baseline FVIII ≤2%) who followed a
standard fixed prophylactic regimen over a period of at least
75 EDs. Of the 510 bleeding episodes that occurred during the
study, 93% were resolved with 1–2 infusions of Advate R©, with
an excellent/good hemostatic response rate of 86%. Part 3 was a
double-blind, randomized, cross-over comparison of the PK of
pilot-scale-prepared Advate R© with commercial-scale-prepared
Advate R©. The bioequivalence of the products was demonstrated
(18). The long-term efficacy and safety of Advate R© in PTPs with
severe or moderate HA (baseline FVIII≤2%) and no previous or
detectable FVIII inhibitors were shown in an open-label, two-part
continuation trial of patients who completed the pivotal phase
TABLE 3 | Studies of Advate ® [from (16)].
Study patients
(n)
Endpoints
Pivotal (108) Pharmacokinetics, efficacy, safety, and
immunogenicity in PTPs
Continuation* (82) Long-term pharmacokinetics, efficacy, safety,
and immunogenicity in PTPs who completed
the Pivotal study
Surgery* (59) Efficacy and safety in PTPs undergoing
surgical/invasive procedures
Pediatric (53) Pharmacokinetics, efficacy, safety, and
immunogenicity in 6-year-old PTPs
Japanese
Registry (15)
Pharmacokinetics, efficacy, safety, and
immunogenicity in PTPs in Japan
PTPs, previously treated patients.
*Patients were eligible to participate in more than one study.
III Advate R© study (19). An integrated analysis of the safety
and efficacy of Advate R© examined the results of six previously
conducted clinical prospective studies in a total of 234 patients
with HA (FVIII ≤ 2%) (median age 14.7 years; range: 0.02–
72.7 years) and concluded that Advate R© was safe and effective.
One PTP developed an inhibitor, but there were no other safety
concerns (20).
In a clinical trial that enrolled 55 PUPs (defined as having
had up to three exposures to an FVIII product at the time
of enrollment), 16 (29.1%) patients who received Advate R©
developed inhibitors: seven (12.7%) had high titers (>5 BU) and
nine (16.3%) had low titers. Inhibitors were detected at a median
of 13 EDs (min-max: 6–26 EDs) (16).
In all of the above-reported studies, no patient had to
withdraw from a clinical trial due to an adverse reaction.
ReFacto AF®
ReFacto AF R© (moroctocog alfa, Pfizer) is a bioequivalent
albumin-free rFVIII produced from the second-generation
product ReFacto R©. It is manufactured using CHO cells grown
in a chemically defined serum- and albumin-free cell culture
medium that, per the definition of a third-generation product,
contains no materials derived from human or animal sources.
ReFacto AF differs from ReFacto R© in that a synthetic peptide
affinity ligand (TN8.2) replaces the murine monoclonal antibody
used in affinity chromatography and a 35-nm viral filtration step
is included in the purification process (21). Sucrose, calcium
chloride dihydrate, L-histidine, sodium chloride, and polysorbate
80 are added as excipients.
Two studies evaluated the properties of Refacto AF R© in 204
PTPs with severe/moderate HA (22). The objectives of the studies
were similar: determinations of the PK equivalence of Refacto
AF R© vs FL-rFVIII (Advate R©-Baxter) and the efficacy and safety
of Refacto AF R© during surgery. These studies used standard
one-stage coagulation and chromogenic assays to measure FVIII
levels. The results showed that BDD-rFVIII PK was equivalent
to FL-rFVIII in 30 PTPs≥12 years of age (Table 5). In a cohort of
PUPs, the PK of Refacto AF R© was evaluated using a chromogenic
assay. In both PTPs and PUPs, the PK of the product included its
stability over long treatment times. Efficacy and safety were also
TABLE 4 | Pharmacokinetic parameters (mean ± SD) of ADVATE® by age group (data from product characteristics documentation).
Pharmacokinetic
parameter
Mean ± SD (n = 7)
(1 to <24 months)
Mean ± SD (n = 32)
(2 to <5 years)
Mean ± SD (n = 24)
(5 to <12 years)
Mean ± SD (n = 35)
(12 to <16 years)
AUC0-t (IU*h/ml) 1,240 ± 330 1,164 ± 424 1,396 ± 506 1,300 ± 469
Incremental recovery at
Cmaxa (IU/dL per IU/kg)
2.1 ± 0.5 1.8 ± 0.4 2.1 ± 0.6 2.1 ± 0.5
t ½ (h) 8.7 ± 1.4 9.5 ± 1.8 11.2 ± 3.5 12.0 ± 2.9
Maximum plasma
concentration
post-infusion (IU/dL)
104 ± 27 91 ± 19 105 ± 34 103 ± 25
Mean residence time (h) 10.4 ±2.5 11.8 ± 2.8 14.3 ± 4.3 14.9 ± 4.6
Volume of distribution at
steady state (dL/kg)
0.4 ± 0.1 0.5 ± 0.1 0.6 ± 0.2 0.6 ± 0.1
Clearance (mL/kg*h) 4.3 ± 1.0 4.8 ± 1.5 4.1 ± 1.5 4.2 ± 1.2
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demonstrated both in the prophylactic use of Refacto AF R© and
in on-demand treatment, including in patients with pre-existing
target joints. Moreover, in all nine patients treated with Refacto
AF R© for surgical support, hemostasis was achieved with minimal
blood loss (≤50mL) and without the need for blood transfusions.
Both studies confirmed the inhibitor safety of Refacto AF R© and
determined that the manufacturing modifications implemented
in the new BDD-rFVIII albumin-free cell culture process were
not associated with neo-antigenicity.
More recently, the United Kingdom Haemophilia Centre
Doctors’ Organization (UKHCDO) National Haemophilia
Database identified a consecutive cohort of 103 PUPs with severe
HA treated with ReFacto AF R© (23). The study monitored time
to inhibitor development and associated risk factors. Inhibitor
development occurred in 35 patients (31.7%) prior to 50 EDs
(P(t≤50) = 0.33, [95% CI: 0.25–0.43]), including 15 (14.5%) with
a high titer (≥5 BU; Pe(t≤50) = 0.16, [95% CI: 0.10–0.25]). The
incidence of inhibitors was comparable to that in previously
published studies of PUPs (24, 25). Anti-rFVIII antibodies were
significantly associated with both high-risk mutations and a
family history of inhibitors. Anti-CHO antibodies were detected
in a low percentage of patients but were without a significant
clinical effect. The authors concluded that, for the PUP cohort
considered in the study, the proportion developing inhibitors
was similar to in previous PUP studies of ReFacto AF R© and
TABLE 5 | Pharmacokinetic study in PTPs treated with ReFacto AF® as
determined in a chromogenic assay (data from product characteristics
documentation).
Pharmacokinetic parameters Mean SD Median
AUC0-t (IU*h/ml) 19.9 4.9 19.9
t1/2 (h) 14.8 5.6 12.7
Clearance (ml/h·kg) 2.4 0.75 2.3
Mean residence time (h) 20.2 7.4 18.0
In vivo recovery (IU/dL/IU/kg) 2.4 0.38 2.5
comparable with PUP studies of other rFVIII concentrates;
nevertheless, a formal comparison of the immunogenicity of
factor VIII products would require a much larger sample.
Kovaltry®
Kovaltry R© (octocog alfa, Bayer) is an unmodified Fl-rFVIII
with an amino acid sequence identical to that of sucrose-
formulated rFVIII (rFVIII-FS; Kogenate R© FS, Bayer, Whippany,
NJ, USA) but developed using innovative techniques (26).
Kovaltry R© and rFVIII-FS use the same cell expression system
(baby hamster kidney [BHK] cells). The product includes the
following excipients: 2.2% glycine, 1% sucrose, 30mM sodium
chloride, 2.5mM calcium chloride, 20mM histidine, and 80
ppm polysorbate 80. The production process incorporates two
dedicated viral clearance steps: a detergent treatment step for
inactivation and a 20-nm filtration step to remove viruses
and potential protein aggregates. Compared with rFVIII-FS,
Kovaltry R© has glycans shifted to higher branched structures and
a somewhat higher degree of sialylation. These modifications
were added to improve the product’s PK, specifically, giving it
slower clearance, a higher area under the curve (AUC) value, and
a longer half-life.
The PK of Kovaltry R© was investigated in PTPs (0–61 years
of age) with severe HA who were administered a dose of 50
IU/kg (Table 6). Kovaltry R© was also extensively studied in the
LEOPOLD clinical trials, comprising three open-label studies
that enrolled patients of all age groups (children, adolescents, and
adults) with severe HA. LEOPOLD I was a multi-center, open-
label, cross-over, uncontrolled study conducted in adolescent and
adult PTPs (age ≥12 years to <65 years) to evaluate the efficacy,
safety, and PK of Kovaltry R© in prophylaxis, and perioperative
coverage. The prophylactic regimen (20–50 IU/kg two or three
times per week) was assigned by the investigator based on the
patient’s individual requirements. The annualized bleeding rate
(ABR) was the primary efficacy endpoint (27). LEOPOLD II was
a multi-center, open-label, cross-over, uncontrolled, randomized
study in adolescent and adult PTPs (age ≥12 years to <65
years) that evaluated the superiority of prophylaxis vs on-demand
treatment with Kovaltry R© over a 1-year treatment period. The
TABLE 6 | Pharmacokinetic parameters for Kovaltry® (50 IU/kg dose) as determined in a chromogenic assay (data from product characteristics documentation).
Patient age
Pharmacokinetic parameter 0 to <6 years (n = 8) 6 to <12 years (n = 10) 12–17 years (n = 5) ≥18 years (n = 21)
AUC [IU h/dL] 1544.7 ± 387.1 1214.5 ± 395.1 1572.0 ± 448.0 2103.4 ± 702.8
Cmaxa [IU/dL] 89.6 ± 27.4 81.6± 17.8 132.5 ± 46.3 133.1 ± 20.4
t½ [h]b 12.1 ± 2.7 12.0 ± 2.1 14.4 ± 5.5 14.2 ± 3.5
MRT IVc [h] 17.7 ± 3.6 17.8 ± 2.9 19.8 ± 5.8 19.9 ± 4.9
Vssd [dL/kg] 0.57 ± 0.13 0.79 ± 0.23 0.71 ± 0.39 0.50 ± 0.11
Clearance [dL/h/kg] 0.033 ± 0.009 0.045 ± 0.016 0.034 ± 0.010 0.027 ± 0.010
AUC, area under the curve.
aMaximum drug concentration in plasma after a single dose.
bTerminal half-life.
cMean residence time after i.v. administration.
dApparent volume distribution at steady state.
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prophylactic regimen was 20–30 IU/kg two times per week or 30–
40 IU/kg three times per week. The treatment group was assigned
by randomization. The primary efficacy endpoint was ABR (28).
LEOPOLD KIDS (part A) was a multi-center, open-label,
uncontrolled study of Kovaltry R© in pediatric PTPs (age ≤12
years; ≥50 EDs). The PK, efficacy, and safety of routine
prophylaxis and the perioperative management of bleeding were
investigated. The primary efficacy variable was the ABR that
occurred during routine prophylaxis within 48 h of the previous
infusion. ABR during prophylaxis, independent of the time of
infusion, was also analyzed. The prophylactic regimen was 25–
50 IU/kg at frequencies of either two times per week, three times
per week or every other day, adapted to the patient’s need by
the investigator. In LEOPOLD KIDS part A, Kovaltry R© values
for the maximum concentration and AUC tended to be lower in
children than in adults. LEOPOLD-KIDS part B, a study in PUPs,
is ongoing (29).
In all of the completed LEOPOLD studies, Kovaltry R©
was shown to be efficacious, whether for prophylaxis, on-
demand treatment, or perioperative hemostasis. The effective
prophylactic dose, defined as achieving a low ABR, was 20–
40 IU/kg, given two or three times per week. The incidence of
treatment-related adverse events was <7% across all LEOPOLD
studies, and no PTPs developed inhibitors during the completed
primary studies (30).
In an actively enrolling clinical trial in PUPs, 6 of 14 treated
patients (42.9% [CI: 17.7–71.1]) developed inhibitors: 3 (21.4%)
had high-titer inhibitors, and 3 (21.4%) had transient low-titer
inhibitors for which no change in therapy was required.
NovoEight®
NovoEight R© (turoctocog alfa, Novo Nordisk) is produced from
CHO cell lines without the use of human or animal plasma.
Turoctocog alfa includes two amino acid chains, a heavy chain
and a light chain, joined by non-covalent bonds. This activated
glycoprotein has the same molecular structure as human FVIII
and is subjected to post-translational changes that are similar to
those of the plasma-derived molecule. The Tyr1680 (total native
length) sulfation site, important for vWF binding, is fully sulfated
in the turoctocog alfa molecule. The high affinity with vWF helps
to reduce the renal clearance of the product and prolong its
half-life. Sucrose, sodium chloride, L-histidine, polysorbate 80, L-
methionine, calcium chloride dihydrate, sodium hydroxide, and
hydrochloric acid are the excipients. Viral inactivation is ensured
by detergent inactivation and a 20-nm nano-filtration step.
Three multicenter, open-label, uncontrolled studies were
conducted to evaluate the safety and efficacy of turoctocog alfa in
the prevention and treatment of bleeding in PTPs with severe HA
(FVIII ≤1%). The studies included 213 patients: 150 adolescent
and adult patients >12 years of age without inhibitors and
with ≥150 EDs, and 63 pediatric patients <12 years of age
without inhibitors and with ≥50 EDs. Of these 213 patients,
187 participated in the extension safety study. Treatment with
turoctocog alfa was shown to be safe and effective for bleeding
treatment and for prophylaxis in 14 patients undergoing a total
of 14 surgical interventions, including 13 major and 1 minor
operation; hemostasis was achieved in all surgical interventions,
and no failure was reported.
The efficacy and safety of turoctocog alfa were evaluated in
the guardian 1 trial (31). Its primary objective was to evaluate
safety in adolescent and adult PTPs with severe HA, especially the
incidence of FVIII inhibitor development. Other endpoints were
efficacy during bleeding episode treatment, bleeding control, and
ABR. The study concluded that turoctocog alfa was safe and
well-tolerated in adolescent and adult patients with HA.
A multicenter, multinational, open-label, sequential dosing
PK study comparing turoctocog alfa with Advate R© was
conducted in 23 patients with severe HA (32). The results of
the primary PK were comparable between the two products. The
90% CI for the treatment ratio of Advate R© to turoctocog alfa was
within the acceptable bioequivalence interval of 0.8–1.25.
Guardian 3 evaluated the safety and efficacy of turoctocog
alfa in pediatric patients 0–11 years of age with severe HA
(FVIII <1%). Patients with >50 EDs to any FVIII product were
included in the study (33). The primary objective and all of
the efficacy endpoints were identical to those in guardian 1.
No patients developed FVIII inhibitors during the study. Three
serious adverse events occurred that were not related to the study
medication: soft-tissue injury, viral gastroenteritis, and device-
related infections. Overall, the authors concluded that turoctocog
alfa is safe and well-tolerated in pediatric patients with HA.
A secondary endpoint in the guardian 1 and 3 studies was
HRQoL related to the use of turoctocog alfa. Those results
showed a fairly stable HRQoL for patients already treated with
prophylaxis (34). The greatest improvement in HRQoL was
seen in patients who switched from on-demand therapy to
prophylaxis. Of the 13 surgeries (10 major, 3 minor) assessed
throughout the guardian 1 and 3 studies, the hemostatic response
achieved with turoctocog alfa was reported as excellent or good in
all of them.
All patients in the guardian 1 and 3 studies or in phase 1
PK trials were eligible for participation in the extension study,
guardian 2, which assessed the efficacy and safety of turoctocog
alfa in prophylaxis or on-demand treatment in PTPs of all
ages. The primary safety endpoint was the frequency of FVIII
inhibitor development. Efficacy endpoints included ABR during
prophylaxis, hemostatic response in the treatment of bleeds, and
the number of injections required to treat bleeds. The results
showed that the extended use of turoctocog alfa was safe and
effective in the prevention and treatment of bleeding episodes in
patients of all ages (35).
The clinical trial GUARDIANTM 4 will assess the efficacy
and safety of turoctocog alfa in the prevention and treatment
of bleeds in treatment-naïve HA patients (36). GUARDIANTM
5 is assessing the safety and efficacy of turoctocog alfa in the
long-term prevention and treatment of bleeding episodes. The
PK parameters of turoctocog alfa in patients with severe HA are
reported in Table 7.
Nuwiq®
Simoctocog alfa (Nuwiq R©, Octapharma-Kedrion) is a BDD-
rFVIII produced in genetically modified human embryonic
kidney cells, rhFVIII, and so is defined as a fourth-generation
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TABLE 7 | Pharmacokinetic profile of Turoctocog Alfa in PTPs with severe HA (coagulation assay) (data from product characteristics documentation).
Patient age
PK parameters 0 to <6 years (n = 14) 6 to <12 years (n = 14) ≥12 years (n = 33)
In vivo recovery (IU/ml)/(IU/kg) 0.018 (0.007) 0.020 (0.004) 0.022 (0.004)
AUC (UI*h)/ml) 9.92 (4.11) 11.09 (3.74) 15.26 (5.77)
Clearance (ml/h/kg) 6.21 (3.66) 5.02 (1.68) 3.63 (1.09)
t ½ (h) 7.65 (1.84) 8.02 (1.89) 11.00 (4.65)
Vss (ml/kg) 56.68 (26.43) 46.82 (10.63) 47.40 (9.21)
Cmax (IU/ml) 1.00 (0.58) 1.07 (0.35) 1.226 (0.41)
Mean values are reported.
Cmax, maximum drug concentration in plasma after a single dose; VSS, apparent volume distribution at steady state.
rFVIII product (37, 38). It consists of a heavy chain followed
by a 16-amino acid linker sequence and a light chain.
The molecule is produced with human post-translational
modifications but without human- or animal-derived materials
being added to the serum medium. Because of its specific post-
translational modifications, a decreased immunogenicity has
been hypothesized. The excipients are sucrose, sodium chloride,
calcium chloride bihydrate, arginine hydrochloride, sodium
citrate bihydrate, and poloxamer 188. The purification process
comprises five chromatographic steps, S/D treatment, and 20-nm
nanofiltration in order to minimize the risk of pathogens in the
final product.
Three studies (GENA 01, GENA 08, and GENA-03) were
carried out in 135 PTPs ≥12 years (74 adult and 61 pediatric
patients) with severe HA treated with simoctocog alfa for
bleeding episodes or the prevention of bleeding during surgery
(39, 40). In the 22 patients included in GENA-01, 91% of
the 986 recorded bleeding episodes were resolved with one
intravenous infusion of concentrate. Replacement therapy with
simoctocog alfa was rated as excellent or good for 94% of the
bleeding episodes. Hemostasis achieved with the preparate in
the two surgeries that occurred during the study was also rated
as excellent.
GENA 08 evaluated 32 patients age≥18 years whowere placed
on standard prophylaxis with simoctocog alfa for the prevention
or treatment of hemorrhagic events. Hemostatic prophylaxis
during surgery was also determined (41). In patients receiving
the product prophylactically, an average of 0.19 bleeds per month
were recorded for each patient. Treatment with the concentrate
was rated as excellent or good based on the control of themajority
of episodes (81.5%). Almost all hemorrhages were resolved with a
single injection. In the five surgeries carried out during the study,
the drug was rated as excellent in preventing bleeding during four
of the operations and moderately efficacious in one.
GENA-03 evaluated the efficacy of simoctocog alfa in the
treatment of bleeding episodes in 59 children 2–12 years of age.
Resolution in 81% of the bleeding episodes was achieved with one
or two injections (42). The efficacy of prophylaxis vs on-demand
treatment with simoctocog alfa in previously treated adults with
severe HA was investigated in an indirect analysis comparing
the results of the GENA-01 (on-demand arm) and GENA-08
(prophylaxis arm) trials. The superiority of prophylaxis (ABR 2.3;
CI: 1.5–3.4) over on-demand treatment (ABR 57.7; CI: 43.3–76.9)
was shown.
Prospective non-registrative trials, such as the extension
studies GENA-11 (extension of GENA-01) and GENA-
13 (extension of GENA-03) and the new study GENA-09
and its extension GENA-04, have also been carried out
(43). The PK profiles of simoctocog alfa with respect to
prophylaxis, breakthrough bleeding, and surgical prophylaxis
were investigated in 22 PTPs in a single center in Russia.
GENA-21 (NuPreviq), a prospective, multicenter, open-label,
phase III study evaluating PK-guided prophylaxis vs on-demand
treatment with simoctocog alfa in 66 adult PTPs with severe
HA, was recently completed. Personalized prophylaxis with
simoctocog alfa was shown to be a more convenient treatment
in the 58% of patients who were able to extend the injection
intervals from three times weekly to twice weekly or less. In
addition to less factor consumption, a lower ABR was recorded
in this group (44).
To assess the efficacy of simoctocog alfa with respect to
surgical prophylaxis, an integrated analysis of five studies
(GENA-01, GENA-03, GENA-04, GENA-08, and GENA-09) was
carried out due to the limited number of PTPs enrolled in each
study. Overall, 19 patients underwent 34 surgical procedures (20
minor and 14major). Drug efficacy was rated as excellent or good
in 100% of the minor and 92% of the major operations. None of
the patients developed inhibitors.
Finally, the GENA-05 (NuProtect) trial evaluated the
immunogenicity, safety, and efficacy of simoctocog alfa in PUPs
with severe HA (45). Data from a preplanned interim analysis
were analyzed for 66 PUPs with ≥20 EDs. The authors reported
that 8 of the patients developed inhibitors after a median of
11.5 EDs (range 6–24); low-titer inhibitors were observed in 5
patients (4 transient). The cumulative incidence (CI) was 12.8%
(4.5–21.2%) for high-titer inhibitors and 20.8% (10.7–31.0%) for
all inhibitors. The median value of ABR was 0 for spontaneous
bleeds and 2.40 for all other bleeding in the inhibitor-free period.
Simoctocog alfa turned out to be effective, being excellent or
good in treating 91.8% of the hemorrhagic episodes, and was
also effective in surgical prophylaxis, being excellent or good for
eight (89%) interventions and moderate for one (11%). No side
effects or adverse reactions were reported (46). However, the PK
of simoctocog alfa, in particular its half-life, was generally not
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TABLE 8 | Pharmacokinetic profile of Simoctocog Alfa (dose: 50 IU/Kg) in
pediatric, adolescent, and adult PTPs with severe HA (chromogenic substrate
assay) (data from product characteristics documentation).
Patient age
Pharmacokinetic
parameter
2–5 years
(n = 13)
6–12 years
(n = 12)
18–65 years
(n = 20)
AUC (h*UI/ml) 11.7 ± 5.3 13.2 ± 3.4 22.6 ± 8.0
t 1/2 (h) 9.5 ± 3.3 10.0 ± 1.9 14.7 ± 10.4
IVR (%/UI/kg) 1.9 ± 0.3 1.9 ± 0.4 2.5 ± 0.4
Clearance (ml/h/kg) 5.4 ± 2.4 4.3 ± 1,2 3.0 ± 1.2
Values reported are mean ± SD.
superior to those of third-generation rFVIII concentrates. The
PK of simoctocog alfa is reported in Table 8.
Afstyla®
Lonoctocog Alfa (Afstyla R©, CSL Behring) is a unique, single-
chain rVIII molecule. It has a truncated B-domain and heavy and
light chains covalently linked to form a stable and homogeneous
compound. The molecule binds with high affinity to vWF, which
results in its increased stability and protection from degradation.
Lonoctocog alfa is produced by recombinant DNA technology
in CHO cells. L-histidine, calcium chloride, sodium chloride,
sucrose, and polysorbate 80 are the excipients. Safety from
infective agents is ensured by chromatography, S/D treatment,
and serial nanofiltration.
Lonoctocog alfa was shown to be effective for prophylaxis,
treatment, and the surgical management of bleeding episodes
in PTPs with severe HA. Two prospective, non-comparative,
multicenter trials (AFFINITY program) were carried out, one
in children and the other in adolescents/adults. Eligible patients
had been treated with an FVIII product for 50–150 EDs. The
co-primary efficacy endpoints were the treatment success rate
(excellent or good) and ABR in routine prophylaxis, which were
compared with on-demand treatment (47). The three-part study
included adolescent/adult patients ≥12–65 years of age. Part
1 evaluated the PK and short-term safety of a single dose of
lonoctocog alfa. Patients who completed Part 1 participated in
Part 2, which compared prophylaxis with on-demand treatment.
Part 3 included 173 other PTPs, 146 of whom were treated on
prophylaxis three times per week.
In the Part 1 study on 27 PTPs, the half-life of lonoctocog
alfa was slightly longer (14.5 ± 3.8 vs. 13.3 ± 4.4 h) than that
of Recombinate R©, and clearance was 28–31% lower. In a post-
hoc sub-analysis, the vWF antigen level for both products was
shown to have a positive effect on half-life and a negative effect
on clearance. This finding suggests that stronger binding to
vWF improves the PK profile of FVIII concentrates. In pediatric
PTPs, the half-life was shorter and the clearance longer than in
adolescents and adults (48) (Table 9).
In Parts 2 and 3, the adult/adolescent patients were assigned
to different prophylaxis regimens or on-demand therapy (20–
40 IU/kg every second day or 20–50 IU/kg two to three times
per week) (47, 49). In all prophylactic regimens, a low median
TABLE 9 | Pharmacokinetic parameters in children, adolescents, and adults by
age category following a single i.v. injection of 50 IU/kg of lonoctocog alfa
(chromogenic assay) (data from product characteristics documentation).
Patient age
Pharmacokinetic
parameter
0 to <6
years
(n = 20)
≥6 to <12
years
(n = 19)
≥12 to <18
years
(n = 10)
≥18 years
(n = 81)
IR (IU/dL)/(IU/kg) 1.60 (21.1) 1.66 (19.7) 2.00 (20.8) 1.69 (24.8)
Cmax (IU/dL) 80.2 (20.6) 83.5 (19.5) 106 (18.1) 89.7 (24.8)
AUC0-inf (IU*h/dL) 1,080 (31.0) 1,170 (26.3) 1,960 (33.1) 1,540 (36.5)
t1/2 (h) 10.4 (28.7) 10.2 (19.4) 14.2 (26.0) 14.3 (33.3)
Mean residence time
(h)
12.4 (25.0) 12.3 (16.8) 20.4 (25.8) 20.0 (32.2)
Clearance (mL/h/kg) 5.07 (29.6) 4.63 (29.5) 2.90 (34.4) 3.80 (46.9)
Vss (mL/kg) 71.0 (11.8) 67.1 (22.3) 55.2 (20.8) 68.5 (29.9)
Values are reported as the arithmetic mean, coefficient of variation [%].
IR, incremental recovery; Cmax, maximum drug concentration in plasma after a single
dose; VSS, apparent volume distribution at steady state.
ABR of 1.14 (Q1, Q3: 0.0, 4.2) and a median of spontaneous
ABR of 0.00 (Q1, Q3: 0.0, 2.4) were recorded. The hemostatic
efficacy was good or excellent based on a 93.8% control rate
for bleeding episodes. The 13 patients who underwent 16
surgical procedures were given lonoctocog alfa for hemostatic
prophylaxis. In the sub-analysis of perioperative management,
the efficacy of lonoctocog alfa was rated as excellent or good
in 100% of the procedures. Data on inhibitor incidence in
PUPs participating in the ongoing CSL627 UNDERSCORE 3001
extension study are awaited.
EHL rFVIII
Elocta®
Efmoroctocog alfa (Elocta R©, Sobi-Biogen) is a first-in-class
fusion protein consisting of a single molecule of human
BDD-rFVIII covalently linked to the dimeric Fc domain of
human immunoglobulin G1 (rFVIII-Fc). The excipients used
are sucrose, sodium chloride, L-histidine, calcium chloride
dihydrate, and polysorbate 20. The half-life of efmoroctocog alfa
is about 1.5 times longer than that of conventional pd-FVIII and
of rFVIII products.
The efficacy of efmoroctocog alfa in prophylaxis, treatment
of acute hemorrhage, and perioperative management has been
investigated in two open-label, non-comparative, multinational
phase III trials enrolling PTPs ≥12 (A-LONG) or <12 (Kids A-
LONG) years of age who had severe HA. Adults and adolescents
were eligible for A-LONG if they had been treated with any FVIII
product for≥150 EDs and had a history of≥12 bleeding events in
the 12 months prior to the study. Children were eligible to enter
Kids A-LONG if they had been treated with any FVIII product
for ≥50 EDs (50).
The A-LONG and Kids A-LONG studies demonstrated the
EHL of efmoroctocog alfa (1.4- to 1.8-fold longer than that of
Recombinate R©). These pivotal phase III trials also showed that
the routine prophylactic administration of efmoroctocog alfa in
PTPs (1–2 times per week in adults/adolescents≥12 years of age;
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twice-weekly in children <12 years of age) was well tolerated,
with no evidence of increased immunogenicity. In addition,
efmoroctocog alfa was effective in preventing bleeding episodes,
including in target joints. Prophylaxis with efmoroctocog alfa
was also associated with maintained or increased physical activity
in the majority of patients, including those with target joints
at baseline. Recommended long-term prophylaxis consists of
intravenous injections of efmoroctocog alfa every 3–5 days (51).
The ASPIRE extension study was completed in 2018. The
final results demonstrated the safety and sustained efficacy
of efmoroctocog alfa for up to 4 years in PTPs with severe
HA. Data from the study also showed the safety and efficacy
of efmoroctocog alfa in the parent trials with respect to the
prevention and treatment of bleeding events, including in the
surgical setting (52). No inhibitors, treatment-related serious
adverse events or deaths were reported. The ABR remained
low: with individualized rFVIII-Fc prophylaxis, the median
spontaneous ABR across all of the studied age groups was<1 and
the median spontaneous joint ABR was 0. Improved joint-health
scores demonstrated a clinical benefit beyond the low bleeding
rates. Both A-LONG and Kids A-LONG exclusively enrolled
PTPs with severe HA. Since the cumulative risk of inhibitor
development is higher in PUPs than in PTPs (∼30 % vs. 2–3 per
1,000 patient-years), an open-label, multicenter, single-arm phase
III study (PUPs A-LONG) is evaluating the safety and efficacy of
efmoroctocog alfa in the prevention and treatment of bleeding
episodes in PUPs <6 years of age who have severe HA. The
primary endpoint is the development of inhibitors; secondary
objectives are efficacy, factor consumption, and experience with
immune tolerance induction in participants with inhibitors (53).
Although susceptible to over- or under-estimation, an interim
analysis of A-LONG PUPs is currently available in anticipation
of the final data. Among the 95 enrolled PUPs, 89 received the
studied treatment, of whom 20 were started on a prophylactic
regimen and 69 on an episodic regimen. Among the latter, 50
patients were switched to prophylaxis, such that the prophylactic
arm of the study consisted of 72 pediatric patients. The pre-
planned PUP-A interim analysis, based on a data cut-off of 12
March 2018, showed that the study enrolled a high proportion
of patients with a family history of inhibitors (20%), a known
risk factor for inhibitor development. According to the primary
analysis (68 patients with≥10 EDs), inhibitors occurred in 30.9%
of patients (n= 21); the rate of high-titer inhibitors was 14.7% (n
= 10). High-titer inhibitors developed after up to 11 EDs (median
8; range 4–11) (54, 55). Efmoroctocog alfa prophylaxis was well-
tolerated and efficacious, with an overall median ABR of 1.16 (0,
4.14) and no spontaneous joint bleeding. The PK profile of the
product is reported in Table 10.
Data on inhibitor frequency in PTPs and PUPs using all of the
rFVIII products are reported in Table 11.
DISCUSSION
Following the outbreak in the 1980s of blood-borne infectious
diseases (particularly HIV and HBV/HCV infections) in
hemophilia patients who received pd-FVIII products that had not
TABLE 10 | Pharmacokinetic profile of efmoroctocog alfa (coagulation and
chromogenic assays) (data from product characteristics documentation).
Pharmacokinetic
parameters
ELOCTAa ELOCTAb
(n = 28) (n = 27)
AUC/dose
(UI*h/dL per UI/kg)
51.2
(45.0–58.4)
47.5
(41.6–54.2)
Cmax (UI/dL) 108
(101–115)
131
(104–165)
Clearance
(mL/h/kg)
1.95
(1.71–2.22)
2.11
(1.85–2.41)
t½ (h) 19.0
(17.0–21.1)
20.9
(18.2–23.9)
Mean residence
time (h)
25.2
(22.7–27.9)
25.0
(22.4–27.8)
Vss (mL/kg) 49.1
(46.6–51.7)
52.6
(47.4–58.3)
Values are reported together with their 95% confidence intervals.
VSS, apparent volume distribution at steady state.
aCoagulation assay.
bChromogenic assay.
been subjected to virus inactivation or removal treatments, the
manufacturers of those products introduced virus sterilization
steps into their production methods and increased the purity
of the preparations via DNA genetic engineering, thus greatly
improving safety. All of the rFVIII products currently available
in Italy have been tested in well-conducted clinical trials in which
they were shown to be effective and safe. However, the ever-
increasing purity of the molecule has made these preparations
more susceptible to inhibitor development than was the case
with pd-FVIII concentrates. Consequently, there is currently an
urgent need to minimize the risk of inhibitor development linked
to replacement treatment/prophylaxis with rFVIII products. This
is especially the case for high-titer inhibitors, which, according to
clinical studies carried out worldwide, mainly develop in PUPs
after≥ 25/50 EDs.
The first-generation rFVIII molecules Recombinate R© and
Kogenate R© were introduced in Italy in the 1990s. Recombinate R©
is currently distributed in Italy by BIOVIIIx. The characteristic of
the product that accounts for its continued use is its stabilization
by human serum albumin and polyethylene glycol (PEG 3350).
The covalent linkage of polyethylene glycol (PEGylation) to
FVIII increases the molecular weight and size of the protein
by surrounding it with a hydrophilic cloud. This molecular
change is thought to have a protective effect, reducing the
product’s susceptibility to proteolytic activity and degradation.
PEGylation also changes the surface charge of the protein,
which may interfere with its clearance, as the half-life of
PEGylated rFVIII is longer than that of non-PEGylated FL-
rFVIII (56). In addition, co-transfection of rvWFwith the rFVIII-
encoding plasmid during the initial production process not
only helps to stabilize Recombinate R© but may also protect it
from inhibitor development. The putative modulatory role of
vWF in the development of inhibitors in patients with HA is
being intensely investigated, and differences in immunogenicity
between pd-FVIII and rFVIII concentrates have been attributed
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TABLE 11 | Rate of total and high-titer inhibitors in PTPs and PUPs using rFVIII products in Italy.
Recombinant product Total incidence
of inhibitors in
PTPs (%)
Incidence of
high-titer
inhibitors in
PTPs (%)
Total incidence of
inhibitors in PUPs (%)
Incidence of high-titer
inhibitors in PUPs (%)
Recombinate® (Baxter-Bioviiix): first-generation
full-length rFVIII
0.123a 0.55 30.5a 12.9
ReFacto AF® (Pfizer): third-generation BDD-rFVIII – – 33 14.5
Advate AF® (Bayer): third generation full-length rFVIII – – 29.1 12.7
Kovaltry® (Bayer): third-generation full-length rFVIII 0 0 Ongoing
LEOPOLD KIDs (Part B)
study
Ongoing
LEOPOLD KIDs (Part B)
study
Novoeight® (Novo Nordisk): third-generation BDT
rFVIII
0 0 Ongoing guardian 4
study
Ongoing guardian 4
study
Nuwiq® (Octapharma-Kedrion): third-generation
BDD-rFVIII
0 0 20.8 12.8
Afstyla® (CSL Behring): third-generation single-chain
rFVIII
0 0 Ongoing
CSL627 UNDERSCORE
3001
extension study
Ongoing
CSL627 UNDERSCORE
3001
extension study
Elocta® (Biogen-Sobi): extended half-life BDD- rFVIIIb 0 0 30.9 14.7b
rFVIII, recombinant factor VIII; BDD, B-domain-deleted; PUPs, previously untreated patients; PTPs, previously treated patients.
a Including high titer, low titer, and transient inhibitors.
b Interim analysis of A LONG study PUPs.
to vWF (57–61). These considerations may explain the trend
of Recombinate R© to show a longer half-life over time (Table 2)
and a similar or lower rate of high-titer inhibitors in PUPs
(11, 62) (Table 11). Moreover, the absence of polysorbate 80
in the concentrate improves the safety of the product (63). In
PUPs and PTPs treated with Recombinate R© over many decades,
there have been no adverse reactions or side effects attributable
to continuous exposure to the excipient PEG, despite a study
showing its potential accumulation or damage (e.g., vacuolation
in epithelial cells of the choroid plexus) in tissues (64).
Advate R© (octocog alfa), a third-generation, human-protein-
free FL-rFVIII, is derived from Recombinate R© and has similar
efficacy, safety, and immunogenicity in PTPs and PUPs with
severe HA. However, Advate R© and other rFVIII products
differ from Recombinate R© in that their excipients include
polysorbate 80.
The BDD-rFVIII ReFacto AF R© is an innovative structural
modification of FVIII derived from ReFacto R©. Its efficacy is
equivalent to that of FL-rFVIII products. The immunogenicity
of ReFacto AF R© in PUPs was evaluated in a study conducted
by UKHCDO. The results showed a slightly high incidence of
high-titer inhibitors (14.5%) in PUPs.
Kovaltry R©, a derivative of Kogenate FS R©, is an unmodified
FL-rFVIII produced using a genetically engineered BHK cell
line. Its post-translational modifications are similar to those
of endogenous FVIII, including glycosylation and tyrosine
sulfation, which account for the high affinity of Kogenate FS R© for
vWF, in turn slightly prolonging its half-life. The results from the
Leopold study confirmed the efficacy and safety of Kovaltry R© for
twice/thrice weekly prophylaxis, on-demand treatment, and the
control of perioperative bleeding in patients of all ages. Moreover,
at least within the completed primary studies, no FVIII inhibitors
developed in PTPs. Anti-HSP70 antibodies were detected in some
patients but were without any clinical effect.
Turoctocog alfa-rFVIII (Novoeight R©) was the first BDT-
rFVIII. Its high affinity for vWF accounts for its slightly longer
half-life. The guardian study of a large population of PTPs
with severe HA demonstrated that turoctocog alfa is effective
and safe in preventing and treating bleeding, is well tolerated,
and is not associated with unexpected safety issues or FVIII
inhibitor development. A PK study comparing turoctocog alfa
with Advate R© showed that the primary PK parameters of the two
products were comparable.
Of particular interest is the BDD-rFVIII simoctocog
alfa (Nuwiq R©), the first product obtained from a human
embryonic kidney cell line. The GENA study and its extensions
demonstrated that simoctocog alfa was a good/excellent rFVIII
in adult and pediatric PTPs, whether for prophylaxis, on-demand
treatment, or intraoperative bleeding prevention. Definitive data
on inhibitor development in a large population of PTPs enrolled
in various prospective trials, as well as preliminary data from the
NuProtect study in PUPs, suggest a low inhibitor rate in patients
treated with simoctocog alfa.
Lonoctocog alfa (Afstyla R©) is a unique single-chain
rFVIII. Its safety, efficacy, and PK profile were evaluated
in two open-label studies, one in children and the other in
adolescents/adult populations. The results of those studies
showed good/excellent hemostatic efficacy both in the control
of episodic hemorrhagic events and in bleeding prophylaxis. In
addition, the adolescent/adults study demonstrated hemostatic
efficacy during the perioperative management of bleeding in
patients undergoing surgical procedures. The high affinity of
lonoctocog alfa for vWF results in its stabilization and reduced
clearance of rFVIII molecules. Data on inhibitor incidence in
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PUPs from the ongoing CSL627 UNDERSCORE 3001 extension
study are not yet available.
Efmoroctocog alfa (Elocta R©), a BDD-human r-FVIII
covalently linked to the Fc domain of human IgG1, is the only
EHL rFVIII commercially available in Italy. The half-life of
efmoroctocog alfa is 1.5–1.8 times longer than that of other,
conventional rFVIII products (19 h and 12–14 h in patients ages
≥12 and <12 years, respectively). Data from pivotal phase III
studies (A-LONG in adults and adolescents ≥12 years of age;
Kids A-LONG in children <12 years of age) and an extension
study (ASPIRE) demonstrated the long-term effectiveness of
efmoroctocog alfa for the treatment of acute bleeding episodes,
perioperative management and routine prophylaxis in PTPs with
severe HA.
Routine prophylaxis consisting of intravenous injections every
3–5 days is recommended, although once weekly may be suitable
for some patients. Neither inhibitor development nor severe
adverse events have been reported. Preliminary data from an
interim analysis of the PUPs A-LONG ongoing study now
available would confirm the hemostatic efficacy of efmoroctocog
alfa. The cumulative incidence of inhibitor development is
30.9% while the rate of high-titer inhibitor development is
14.7%. Efmoroctocog alfa used prophylactically is well-tolerated
and efficacious, with a very low median ABR overall and no
spontaneous joint bleeding.
CONCLUSION
Currently, the National Health Care System in Italy guarantees
the availability of rFVIII products for the prophylaxis and
episodic treatment of patients with severe HA. Third-generation
rFVIII concentrates represent a wide range of high-quality
products that offer efficacy and safety in all therapeutic regimens.
Today, with the availability of EHL-rFVIII, the quality of life
of both patients and caregivers is improving. Nonetheless,
the first-generation rFVIII Recombinate R©, far from being
obsolete, continues to be effective and safe. The development
of inhibitors, the most serious complication of replacement
therapy, seems to be of very limited importance in PTPs
who have switched to third-generation rFVIII products. In
clinical studies, all of these newly developed concentrates
have demonstrated efficacy and safety; nevertheless, they
do not seem to be less immunogenic in PUPs than other
rFVIII products. Despite the structural and functional
improvements of new rFVIII concentrates, the incidence of
high-titer inhibitors in PUPs remains a very significant and still
unsolved problem.
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